Clinical Trials
30 trialsNCT04108195 2026-06-05
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04133636 2026-06-05
CARTITUDE-2
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04722146 2026-06-05
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05438043 2026-06-05
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05552222 2026-06-05
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06577025 2026-06-05
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04933539 2026-06-04
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT06615479 2026-06-04
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT06974786 2026-06-04
FASTER
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT03899155 2026-06-03
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT07623798 2026-06-03
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Not yet recruiting
NCT03652064 2026-06-02
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT04915248 2026-06-02
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2 Recruiting
NCT05231629 2026-06-02
MASTER-2
University of Alabama at Birmingham
Phase 2 Recruiting
NCT06953960 2026-06-02
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
AbbVie
Phase 1/2 Recruiting
NCT07095452 2026-06-02
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
Phase 2/3 Recruiting
NCT04139304 2026-06-01
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
AIDS Malignancy Consortium
Phase EARLY_PHASE1 Recruiting
NCT05434689 2026-06-01
COMMANDER
University of Alabama at Birmingham
Phase 1/2 Active not recruiting
NCT06918002 2026-06-01
ElLen
Intergroupe Francophone du Myelome
Phase 3 Recruiting
NCT03290950 2026-05-29
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07555938 2026-05-27
CEVOLUTION
Hoffmann-La Roche
Phase 3 Recruiting
NCT07605416 2026-05-26
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT01946477 2026-05-22
POM MM 014
Celgene
Phase 2 Completed
NCT04824794 2026-05-19
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Phase 1/2 Terminated
NCT06287944 2026-05-18
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
City of Hope Medical Center
Phase 1 Recruiting
NCT03937635 2026-05-15
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04566328 2026-05-15
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT06015724 2026-05-15
DARANIVOVAX
Georgetown University
Phase 2 Recruiting
NCT07082270 2026-05-15
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT05623020 2026-05-14
MagnetisMM-6
Pfizer
Phase 3 Recruiting